1
|
Li L, Ma S, Qin Y, Liu L. Enhanced UHPLC-MS/MS determination of a therapeutic heptapeptide mimic for inflammatory-related diseases in rat plasma: application to a pharmacokinetic study. RSC Adv 2019; 9:32699-32711. [PMID: 35529728 PMCID: PMC9073091 DOI: 10.1039/c9ra05114g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Accepted: 09/21/2019] [Indexed: 11/21/2022] Open
Abstract
The seven amino acid peptide, GQTYTSG (named as SP), a peptide mimic derived from hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) has presented remarkable anti-inflammatory activities in previous experiments, indicating that it could be a novel therapeutic peptide candidate for different inflammation-related diseases, such as HCV infection and asthma. A heptapeptide mimic discovery study highlighted the need for the development of quantitative bioanalytical assays for measuring the levels of SP. Herein, a reliable and sensitive ultrahigh-performance liquid chromatography (UHPLC) with tandem mass spectrometry (MS/MS) assay was established and validated for the determination of SP in rat plasma. C-11, with two amino acid substitutions compared to SP (Glycine 1 and Glycine 7) and a disulfide, acted as an internal standard (IS). SP and C-11 were isolated from acidified plasma using protein precipitation and the extracts were analyzed by reversed-phase UHPLC-MS/MS detection. We used an SHIM-PACK GISS C18 (2.1 × 100 mm, 1.9 μm) column with water containing 0.2% acetic acid as the aqueous mobile phase and methanol as the organic mobile phase with a 0.3 mL min-1 flow rate. We used an AB SCIEX TripleQuad™ 5500 mass spectrometer equipped with a TurboIon Spray interface and operated it in positive-ion mode. Multiple reaction monitoring (MRM) was used for the quantification of the precursor to the product ion at m/z 713.3 → 432.2 for SP and m/z 803.2 → 539.1 for IS. The method was fully validated according to the US Food and Drug Administration (FDA) guideline (2018), and provided satisfactory accuracy, precision, and reproducibility for the quantification of SP in rat plasma. Excellent linearity was achieved (r > 0.9977) over a linear dynamic range of 0.1-200 ng mL-1 with a lower limit of quantification (LLOQ) of 0.1 ng mL-1. The validated assay was applied to gain the pharmacokinetic (PK) parameters and the concentration-time profile for SP after subcutaneous administration in rats.
Collapse
Affiliation(s)
- Liang Li
- Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry Shanghai 200437 PR China +8621-65043855
- State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR China
- Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation Shanghai 200437 PR China
| | - Shumei Ma
- Department of Pharmacology, School of Pharmacy, Fudan University Shanghai 201203 PR China
| | - Yan Qin
- Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry Shanghai 200437 PR China +8621-65043855
- State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR China
- Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation Shanghai 200437 PR China
| | - Li Liu
- Center for Pharmacological Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry Shanghai 200437 PR China +8621-65043855
- State Key Laboratory of New Drug and Pharmaceutical Process Shanghai 201203 PR China
- Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation Shanghai 200437 PR China
| |
Collapse
|
2
|
Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol 2013; 19:7896-7909. [PMID: 24307784 PMCID: PMC3848138 DOI: 10.3748/wjg.v19.i44.7896] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Revised: 09/11/2013] [Accepted: 10/14/2013] [Indexed: 02/06/2023] Open
Abstract
This review focuses on research findings in the area of diagnosis and pathogenesis of hepatitis C virus (HCV) infection over the last few decades. The information based on published literature provides an update on these two aspects of HCV. HCV infection, previously called blood transmitted non-A, non-B infection, is prevalent globally and poses a serious public health problem worldwide. The diagnosis of HCV infection has evolved from serodetection of non-specific and low avidity anti-HCV antibodies to detection of viral nucleic acid in serum using the polymerase chain reaction (PCR) technique. Current PCR assays detect viral nucleic acid with high accuracy and the exact copy number of viral particles. Moreover, multiplex assays using real-time PCR are available for identification of HCV-genotypes and their isotypes. In contrast to previous methods, the newly developed assays are not only fast and economic, but also resolve the problem of the window period as well as differentiate present from past infection. HCV is a non-cytopathic virus, thus, its pathogenesis is regulated by host immunity and metabolic changes including oxidative stress, insulin resistance and hepatic steatosis. Both innate and adaptive immunity play an important role in HCV pathogenesis. Cytotoxic lymphocytes demonstrate crucial activity during viral eradication or viral persistence and are influenced by viral proteins, HCV-quasispecies and several metabolic factors regulating liver metabolism. HCV pathogenesis is a very complex phenomenon and requires further study to determine the other factors involved.
Collapse
|
3
|
Uhde-Holzem K, Schlösser V, Viazov S, Fischer R, Commandeur U. Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9. J Virol Methods 2010; 166:12-20. [PMID: 20138085 DOI: 10.1016/j.jviromet.2010.01.017] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2009] [Revised: 01/20/2010] [Accepted: 01/25/2010] [Indexed: 12/11/2022]
Abstract
The immunogenic properties of chimeric potato virus X (PVX) particles engineered to display the synthetic R9 peptide have been evaluated. The R9 peptide is a consensus sequence derived from diverse variants of the hypervariable region 1 from the hepatitis C virus (HCV) envelope protein E2. Two different constructs were designed, with the R9 peptide expressed either as an indirect fusion via the ribosomal skip 2A (PVX(R9-2A)CP) sequence or as a direct PVX coat protein fusion (PVX(R9)CP). Systemic infection of Nicotiana benthamiana plants was only achieved with PVX(R9-2A)CP constructs, and the presence of the R9 peptide was detected in extracts from these plants by ELISA, Western blot and electron microscopy using specific anti-R9 antibodies. The virus particles were recovered at yields of up to 125mg/kg from leaf material. BALB/c mice immunized with purified PVX(R9-2A)CP particles developed specific anti-R9 IgG titers of up to 1:50,000. Monoclonal anti-R9 antibodies were obtained from the spleen of a mouse immunized with PVX(R9-2A)CP particles and characterized by Western blot and electron microscopy. Sera from patients infected chronically with HCV were found to react specifically with PVX(R9-2A)CP particles in 35% of cases.
Collapse
Affiliation(s)
- Kerstin Uhde-Holzem
- Institute for Molecular Biotechnology (Biology VII), RWTH Aachen University, Worringerweg 1, 52074 Aachen, Germany
| | | | | | | | | |
Collapse
|
4
|
Irshad M, Khushboo I, Singh S, Singh S. Hepatitis C virus (HCV): a review of immunological aspects. Int Rev Immunol 2009; 27:497-517. [PMID: 19065353 DOI: 10.1080/08830180802432178] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The present manuscript represents an updated review on different aspects of immunology involved during hepatitis C virus infection in human beings. This includes a brief mention of HCV structure, presentation of viral components to host immune system, and ensuing immune response and immunopathogenesis occurring during HCV infection. The present article also highlights immunodiagnosis of HCV infection and the current status of immunotherapy available for HCV eradication. Its envelope protein, E2, is the primary mediator of virus attachment and cell entry. CD81 molecule on cell surface acts as a major receptor for viral entry into the host cells. Mature dendritic cells play an important role in presenting viral antigen, activate T-cells, and initiate anti-viral immune response. Relative T-cell populations and release of different cytokines from activated T-cells ultimately determine the clearance or persistence of HCV viremia through cellular and humoral immune responses. Natural killer (NK) cells constitute the first line of host defense against invading viruses by recruiting virus-specific T-cells and inducing antiviral immunity in liver. Diagnosis of acute or chronic hepatitis C virus (HCV) infection is established by serological assays for presence of antibodies against different sets of viral proteins during varied periods post infection. An effective immunotherapy and vaccine against HCV is still awaited.
Collapse
Affiliation(s)
- M Irshad
- Clinical Biochemistry Division, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.
| | | | | | | |
Collapse
|
5
|
Scottà C, Garbuglia AR, Ruggeri L, Spada E, Laurenti L, Perrone MP, Girelli G, Mele A, Capobianchi MR, Folgori A, Nicosia A, Del Porto P, Piccolella E. Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region 1 during acute HCV infection. J Hepatol 2008; 48:216-28. [PMID: 18180071 DOI: 10.1016/j.jhep.2007.09.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2007] [Revised: 09/24/2007] [Accepted: 09/25/2007] [Indexed: 01/29/2023]
Abstract
BACKGROUND/AIMS Several studies suggest that the evolutionary rate of HVR1 sequence in acute HCV hepatitis derives from the action of a continuous immune-driven positive selection. However, these studies have not been performed examining the relationship between HVR1 evolution and the development of specific immunity to autologous HVR1 sequences. METHODS We performed a longitudinal analysis of HVR1 sequences and specific antibodies and CD4+ T cells in ten HCV acutely infected patients with different clinical outcomes (recovery versus persistence). RESULTS We showed that although both recovered and chronically evolving individuals developed IFN-gamma+ T cells specific for Core and NS sequences, HVR1-specific CD4+ T cells were detected only in patients clearing the virus. On the contrary, all patients displayed anti-HVR1 antibodies that recognized sequences exclusively carried by autologous viruses. Measurements of genetic diversity and the number of non-synonymous per synonymous substitutions within HVR1 sequences before and after antibody appearance showed an increase of these parameters only in concomitance with the appearance of anti-HVR1 antibodies. CONCLUSIONS The evidence that anti-HVR1 antibodies favor HVR1 variant selection suggests that viral complexity in chronically infected patients could represent a virus adaptive strategy to escape the continuous selective process mediated by anti-HVR1 antibodies.
Collapse
Affiliation(s)
- Cristiano Scottà
- Department of Cellular and Developmental Biology,"La Sapienza" University of Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Park VM, Mason BC, Krushkal J, Li R, Riely C, Fleckenstein J. Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure. Dig Dis Sci 2007; 52:2540-9. [PMID: 17410445 DOI: 10.1007/s10620-006-9726-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2006] [Accepted: 12/03/2006] [Indexed: 02/08/2023]
Abstract
In a prospective therapeutic trial, features of the hepatitis C quasispecies were investigated as possible markers of therapeutic response. Individuals chronically infected with hepatitis C genotype 1 received antiviral therapy consisting of alpha-interferon plus ribavirin. The study targeted the most rapidly evolving segment of the viral genome, hypervariable region 1 within the envelope-2 gene. Among individuals failing to clear virus in response to therapy, significant differences were observed between quasispecies of African-American and Caucasian subjects. While distance measures for synonymous substitutions were similar between racial subgroups, measures of distance at the amino acid level (nonsynonymous substitutions) varied significantly. Taken together, the observed patterns of variability corresponded to reduced host selection pressure against hypervariable region 1 in African-American nonresponders. Reduced selection pressure was present at baseline and persisted through treatment and follow-up, suggesting population stratification of host factors that influence selection pressure on hepatitis C virus.
Collapse
Affiliation(s)
- Vicki M Park
- Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
| | | | | | | | | | | |
Collapse
|
7
|
Nuzzaci M, Piazzolla G, Vitti A, Lapelosa M, Tortorella C, Stella I, Natilla A, Antonaci S, Piazzolla P. Cucumber mosaic virus as a presentation system for a double hepatitis C virus-derived epitope. Arch Virol 2007; 152:915-28. [PMID: 17238010 DOI: 10.1007/s00705-006-0916-7] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2006] [Accepted: 11/30/2006] [Indexed: 11/26/2022]
Abstract
Chimeric plant viruses are emerging as promising vectors for use in innovative vaccination strategies. In this context, cucumber mosaic virus (CMV) has proven to be a suitable carrier of the hepatitis C virus (HCV)-derived R9 mimotope. In the present work, a new chimeric CMV, expressing on its surface the HCV-derived R10 mimotope, was produced but lost the insert after the first passage on tobacco. A comparative analysis between R10- and R9-CMV properties indicated that R9-CMV stability was related to structural features typical of the foreign insert. Thus, in order to combine high virus viability with strong immuno-stimulating activity, we doubled R9 copies on each of the 180 coat protein (CP) subunits of CMV. One of the chimeras produced by this approach (2R9-CMV) was shown to systemically infect the host, stably maintaining both inserts. Notably, it was strongly recognized by sera of HCV-infected patients and, as compared with R9-CMV, displayed an enhanced ability to stimulate lymphocyte IFN-gamma production. The high immunogen levels achievable in plants or fruits infected with 2R9-CMV suggest that this chimeric form of CMV may be useful in the development of oral vaccines against HCV.
Collapse
Affiliation(s)
- M Nuzzaci
- Department of Biology, Plant Protection and Agrobiotechnology, University of Basilicata, Potenza, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Scottà C, Tuosto L, Masci AM, Racioppi L, Piccolella E, Frasca L. Hypervariable region 1 variant acting as TCR antagonist affects hepatitis C virus-specific CD4+ T cell repertoire by favoring CD95-mediated apoptosis. J Leukoc Biol 2005; 78:372-82. [PMID: 15923217 DOI: 10.1189/jlb.0804456] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
We have described previously that hypervariable region 1 (HVR1) variants of hepatitis C virus (HCV) frequently act as T cell receptor (TCR) antagonists for HVR1-specific helper T cells. These naturally occurring HVR1-antagonistic sequences interfered with the effects of HVR1-agonistic sequences such as TCR down-regulation and early activatory signals. By taking advantage of these findings, in this paper, we have analyzed the fate of these HVR1-specific antagonized CD4+ T cells. We present the evidence that TCR antagonism renders agonist-activated T cells susceptible to bystander CD95-mediated killing by suppressing the expression of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitor proteins. To verify whether the TCR repertoire of a HVR1-specific T cell population could be modified consequently, we used a HVR1-agonistic sequence to induce in vitro CD4+ T cells and another HVR1 sequence with antagonistic property to mediate suppressive phenomena. HVR1-specific T cells were cultured with the agonist alone or with the agonist plus the antagonist. HVR1 specificity and T cell repertoires were followed over time by analyzing TCR beta-variable gene segment by "spectratyping". The results showed that the specificity for the agonist was rapidly spoiled after culture in the presence of the antagonist, and the TCR repertoire was strongly modified as a result of CD95-mediated apoptosis of agonist-specific clonal expansions. These data support the hypothesis that in HCV infection, the generation of TCR antagonists may reshape the T cell repertoire, representing an efficacious immune evasion strategy of a highly mutant pathogen.
Collapse
MESH Headings
- Antigens, Viral/immunology
- Apoptosis/immunology
- CD4-Positive T-Lymphocytes/immunology
- Cell Proliferation
- Cells, Cultured
- Down-Regulation/immunology
- Epitopes, T-Lymphocyte
- Hepacivirus/immunology
- Hepacivirus/pathogenicity
- Humans
- Lymphocyte Activation/immunology
- Receptors, Antigen, T-Cell, alpha-beta/antagonists & inhibitors
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Receptors, Antigen, T-Cell, alpha-beta/immunology
- Serpins/biosynthesis
- Serpins/immunology
- T-Lymphocyte Subsets/immunology
- Viral Proteins/biosynthesis
- Viral Proteins/immunology
- fas Receptor/immunology
Collapse
Affiliation(s)
- Cristiano Scottà
- Department of Cellular and Developmental Biology, La Sapienza University, Rome, 00185, Italy
| | | | | | | | | | | |
Collapse
|
9
|
Piazzolla G, Nuzzaci M, Tortorella C, Panella E, Natilla A, Boscia D, De Stradis A, Piazzolla P, Antonaci S. Immunogenic Properties of a Chimeric Plant Virus Expressing a Hepatitis C Virus (HCV)-Derived Epitope: New Prospects for an HCV Vaccine. J Clin Immunol 2005; 25:142-52. [PMID: 15821891 DOI: 10.1007/s10875-005-2820-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2004] [Indexed: 01/09/2023]
Abstract
A vaccine against Hepatitis C virus (HCV) is urgently needed due to the unsatisfactory clinical response to current therapies. We evaluated the immunological properties of a chimeric Cucumber mosaic virus (CMV), a plant virus engineered to express on its surface a synthetic peptide derived from many HVR1 sequences of the HCV envelope protein E2 (R9 mimotope). Evidence was obtained that the chimeric R9-CMV elicits a specific humoral response in rabbits. Furthermore, in patients with chronic HCV infection, purified preparations of R9-CMV down-modulated the lymphocyte surface density of CD3 and CD8, and induced a significant release of interferon (IFN)-gamma, interleukin (IL)-12 p70 and IL-15 by lymphomonocyte cultures. Finally, an R9 mimotope-specific CD8 T-cell response, as assessed by intracellular IFN-gamma production, was achieved in the majority of the patients studied. Our results open up new prospects for the development of effective vaccines against HCV infection. Moreover, the wide edible host range of CMV makes the production of an edible vaccine conceivable.
Collapse
Affiliation(s)
- G Piazzolla
- Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari, Policlinico, 70124 Bari, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|